A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Advanced Hepatocellular Carcinoma
Спонсор: AstraZeneca AB
Налично на:
БГ
Обобщение
Trial status: Authorised
PFS, ORR, DoR by BICR per RECIST v1.1
Overall Survival (OS)
Описание
PFS, ORR, DoR by BICR per RECIST v1.1
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 273 participants
Интервенции
IMJUDO 20 mg/ml concentrate for solution for infusion.
Drug
IMJUDO 20 mg/ml concentrate for solution for infusion.
БГ
EN